We are live on !
Find out more
SCM
Stonepine Capital Management Portfolio holdings
AUM
$177M
Turnover
41.12%
1-Year Est. Return
91.13%
This Fund
S&P 500
This Quarter Est. Return
+16.86%
1 Year Est. Return
+91.13%
3 Year Est. Return
+230.7%
5 Year Est. Return
+260.67%
10 Year Est. Return
+2,169.5%
AUM
$177M
AUM Growth
-$72.5M
(-29%)
Cap. Flow
+$12.6M
Cap. Flow % of AUM
Cap. Flow %
7.11%
Top 10 Holdings %
Top 10 Hldgs %
44.39%
Holding
107
New
24
Increased
24
Reduced
27
Closed
20
Avg Time Held
Equity + Options
0.6
years
Top 10 Avg Time Held
Equity + Options
0.7
years
Top 20 Avg Time Held
Equity + Options
0.6
years
Avg Time Held Equity only
0.7
years
Top 10 Avg Time Held Equity only
0.8
years
Top 20 Avg Time Held Equity only
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eloxx Pharmaceuticals
ELOX
|
+$5.07M |
| 2 |
Edesa Biotech
EDSA
|
+$3.85M |
| 3 |
Indivior Pharmaceuticals
INDV
|
+$3.63M |
| 4 |
Cabaletta Bio
CABA
|
+$2.85M |
| 5 |
Satellos Bioscience
MSLE
|
+$2.69M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tenax Therapeutics
TENX
|
+$4.03M |
| 2 |
Zevra Therapeutics
ZVRA
|
+$2.46M |
| 3 |
Xoma
XOMA
|
+$2.18M |
| 4 |
Abeona Therapeutics
ABEO
|
+$1.04M |
| 5 |
Inhibikase Therapeutics
IKT
|
+$1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 74.11% |
| 2 | Miscellaneous | 25.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Verastem
VSTM
$786M
| $12.8M | 7.22% |
3,349,627
+47,327
| +1% | +$229K |
2024 Q3
7 quarters
|
|
2
Evolus
EOLS
$480M
| $11M | 6.23% |
1,590,162
-168,929
| -10% | -$997K |
2022 Q3
15 quarters
|
|
|
3
Tenax Therapeutics
TENX
$57.3M
| $9.6M | 5.42% |
660,000
-315,200
| -32% | -$4.03M |
2025 Q4
2 quarters
|
|
4
Nektar Therapeutics
NKTR
$1.24B
| $8.42M | 4.75% |
120,654
+35,654
| +42% | +$2.61M |
2025 Q2
4 quarters
|
|
5
CALL
ADMA Biologics
ADMA
$2.49B
| $7.95M | 4.48% |
650,000
-500,000
| -43% | -$4.56M |
2026 Q1
1 quarter
|
|
|
6
ADMA Biologics
ADMA
$2.49B
| $6.19M | 3.49% |
740,000
| – | – |
2021 Q4
18 quarters
|
|
7
CAMP4 Therapeutics
CAMP
$199M
| $6.07M | 3.43% |
1,389,622
| – | – |
2025 Q4
2 quarters
|
|
8
CALL
Insmed
INSM
$20.9B
| $5.6M | 3.16% |
+40,000
| New | +$4.84M |
2026 Q2
0 quarters
|
|
|
9
Eloxx Pharmaceuticals
ELOX
$43M
| $5.51M | 3.11% |
+397,160
| New | +$5.07M |
2026 Q2
0 quarters
|
|
10
CALL
Ultragenyx Pharmaceutical
RARE
$1.47B
| $5.5M | 3.1% |
+200,000
| New | +$4.97M |
2026 Q2
0 quarters
|
|
11
Kazia Therapeutics
KZIA
$121M
| $4.86M | 2.74% |
345,179
| – | – |
2025 Q4
2 quarters
|
|
12
CALL
Medtronic
MDT
$119B
| $4.38M | 2.47% |
+50,000
| New | +$4.03M |
2026 Q2
0 quarters
|
|
|
13
Indivior Pharmaceuticals
INDV
$3.96B
| $4.1M | 2.31% |
+100,000
| New | +$3.63M |
2026 Q2
0 quarters
|
|
14
Corbus Pharmaceuticals
CRBP
$85.3M
| $3.99M | 2.25% |
425,000
+41,538
| +11% | +$393K |
2025 Q4
2 quarters
|
|
15
CALL
Abbott
ABT
$181B
| $3.8M | 2.14% |
+40,000
| New | +$3.65M |
2026 Q2
0 quarters
|
|
|
16
Satellos Bioscience
MSLE
$136M
| $3.72M | 2.1% |
491,624
+391,624
| +392% | +$2.69M |
2026 Q1
1 quarter
|
|
|
17
Zevra Therapeutics
ZVRA
$601M
| $3.71M | 2.09% |
258,701
-221,299
| -46% | -$2.46M |
2024 Q3
7 quarters
|
|
|
18
Abeona Therapeutics
ABEO
$252M
| $3.44M | 1.94% |
557,284
-189,303
| -25% | -$1.04M |
2025 Q2
4 quarters
|
|
19
CALL
Boston Scientific
BSX
$65.2B
| $3.25M | 1.83% |
+50,000
| New | +$2.72M |
2026 Q2
0 quarters
|
|
|
20
Edesa Biotech
EDSA
$26.8M
| $3.19M | 1.8% |
456,439
+426,439
| +1,421% | +$3.85M |
2025 Q3
3 quarters
|
|
|
21
CALL
Evolus
EOLS
$480M
| $3.15M | 1.78% |
420,000
| – | – |
2026 Q1
1 quarter
|
|
22
CALL
BioMarin Pharmaceuticals
BMRN
$10.6B
| $3.12M | 1.76% |
+50,000
| New | +$2.74M |
2026 Q2
0 quarters
|
|
|
23
Cabaletta Bio
CABA
$249M
| $2.85M | 1.61% |
917,100
+867,100
| +1,734% | +$2.85M |
2025 Q4
2 quarters
|
|
24
AN2 Therapeutics
ANTX
$124M
| $2.67M | 1.51% |
551,692
-162,153
| -23% | -$697K |
2025 Q2
4 quarters
|
|
25
Xilio Therapeutics
XLO
$56.4M
| $2.17M | 1.22% |
225,994
+161,832
| +252% | +$1.35M |
2025 Q4
2 quarters
|
|
Similar funds
RP
MSA
BFAG
MVM
CMP
JESC
WFG
AIS
Stonepine Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, Stonepine Capital Management held 107 positions worth $177M, down 29% from $250M the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Stonepine Capital Management deployed $12.6M of net new capital in Q2 2026, opening 24 new positions and adding to 24 existing holdings. Its largest new stake was Eloxx Pharmaceuticals: 397,160 shares worth $5.51M.
By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 46% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Tenax Therapeutics, an estimated $4.03M trimmed.
- Stonepine Capital Management's largest Q2 2026 buy was Eloxx Pharmaceuticals: 397,160 shares worth $5.51M.
- Stonepine Capital Management added most to Edesa Biotech in Q2 2026, an estimated $3.85M increase.
- Stonepine Capital Management's biggest Q2 2026 reduction was Tenax Therapeutics, cutting an estimated $4.03M.
- Stonepine Capital Management fully exited Xoma in Q2 2026, selling an estimated $2.18M.
- Stonepine Capital Management's ten largest holdings make up 44% of its $177M portfolio in Q2 2026.
- Stonepine Capital Management opened 24 new positions and closed 20 in Q2 2026.
- Stonepine Capital Management's portfolio value fell 29% quarter-over-quarter to $177M.
Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.